Ubiquitination and degradation of the Myc onco-protein are highly regulated events that have an important function in tumourigenesis. A new study by Rosalie Sears and colleagues now identifies Axin, a tumour suppressor protein best known for its role in the Wnt pathway, as a central co-ordinator of this Myc degradation. Loss-of-function mutations in Axin, therefore, directly enhance Myc levels in human tumours.

Ever since the discovery that enhanced expression of a wild-type MYC gene is sufficient to uncover its oncogenic properties in a mouse model of B-cell lymphomagenesis (Adams et al., 1985), it has been accepted in the field that the levels of Myc are an important determinant of normal and pathological cell behaviour. Consequently, the molecular mechanisms that control Myc protein levels have been studied in extensive detail, and we now know that both transcriptional and a plethora of post-transcriptional mechanisms regulate Myc levels in normal and in tumour cells.

For example, Myc is a highly unstable protein that is rapidly turned over by the ubiquitin-proteasome system in normal cells; the rate of turnover is attenuated in many tumour cells. Although several ubiquitin ligases have been shown to associate with Myc, the best understood pathway is the degradation by Fbw7 (Welcker et al., 2004; Yada et al., 2004). Degradation through this pathway is initiated by phosphorylation of Myc at serine 62, which serves as a priming site for binding of Gsk3. Gsk3 then phosphorylates Myc at threonine 58 and T58-phosphorylated Myc is—after a series of intermediate steps—recognized by the Fbw7 ubiquitin ligase, leading to ubiquitinated Myc through the proteasome. This pathway offers a prime example of how degradation of Myc can be disrupted during tumourigenesis: many Burkitt lymphomas harbour point mutations in Myc at either T58 or S62, leading to reduced ubiquitination and enhanced stability (Bahram et al., 2000).

One would expect, therefore, that similar mutations could be found in at least some of the other tumours in which enhanced levels of Myc have an important function. But this does not appear to be the case: despite intensive efforts, no point mutations of MYC have been reported from solid tumours.

So, if point mutants of Myc offer an easy way to enhance protein levels of this protein during tumourigenesis, then why are they never found in solid tumours, despite extensive searches? One answer to this riddle, albeit a partial one, is that other mutations and changes in gene expression occur that can stabilize Myc and that may, therefore, alleviate the necessity for further mutations in Myc itself. Several of these changes affect the kinase cascades that

![Figure 1](https://example.com/figure1.png)

**Figure 1** The figure illustrates the role of Axin in degradation of Myc. Axin facilitates phosphorylation of T58 by Gsk3 and the subsequent de-phosphorylation of S62 by PP2A. Mutations in Axin are found in several tumours and affect different scaffolding roles of Axin, all resulting in enhanced levels of Myc.
control phosphorylation of Myc. For example, the PI3-Kinase pathway is constitutively activated in many tumours by mutations in receptor tyrosine kinases or by loss of the PTEN phosphatase; activation of PI3-Kinase leads to inhibition of Gsk3 activity and subsequently T58 phosphorylation. Similarly, the FBW7 gene is a tumour suppressor gene that is lost in many, most notably colon, carcinomas (Rajagopalan et al., 2004). Finally, a de-ubiquitinating enzyme, Usp28, that antagonizes the function of FBW7 and stabilizes Myc, is expressed at very high levels in breast and colon carcinoma (Popov et al., 2007). Potentially, therefore, many of the mutations found in solid tumours affect Myc turnover, and it is therefore only the genomically relatively stable lymphomas, which resort to mutating Myc itself.

In the current issue of the EMBO Journal, Rosalie Sears and colleagues add an important further piece of evidence to support this concept. In this paper, Arnold et al show that complex formation between Myc and Gsk3 (as well as FBZ1 and two other proteins involved in degradation) is facilitated by the scaffolding protein Axin1. Axin1 has a similar role in several signaling pathways: it is best known for its role in the Wnt pathway, where it acts as a platform for Gsk3-mediated phosphorylation of β-catenin, leading to its degradation by the proteasome pathway. Although the Wnt pathway is intimately linked to Myc function, it appears that the function of Axin1 in Myc degradation is mediated by a complex that is unrelated to that mediating catenin turnover, as a key component of the latter complex, the APC tumour suppressor protein, has no role in Myc turnover. Importantly, Axin1 is a tumour suppressor protein and Arnold et al go on to show that stabilization of Myc in several tumour cell lines correlates with the presence of Axin1 mutations that disrupt its ability to act as a scaffold for degradation of Myc (Figure 1). These data suggest that an additional class of mutations, which may be largely undetected, contribute to the stabilization of Myc by inhibiting FBW7-mediated degradation of the protein. By further highlighting this pathway, they also point to what appears to be the biggest puzzle with regard to our understanding of how this pathway controls Myc function: the T58A and S62A mutations are not only more stable but also show a strongly reduced pro-apoptotic potential; for example, lymphomas that are generated with these mutants in transgenic mice can arise in the presence of wild-type p53 and Arf and thus escape the otherwise obligatory mutations in the p53/Arf pathway, which mediates apoptosis in response to deregulation of wild-type Myc (Hemmam et al., 2005). Furthermore, these mutations have altered gene-regulatory properties. How does this fit together? First, it is possible that the mutations that are selected for during lymphomagenesis affect a hitherto unknown protein interaction of Myc that just happens to bind in a region of Myc that also affects turnover. This idea is supported by the observation that not all mutations of Myc that are found in Burkitt lymphomas stabilize the protein. Alternatively, ubiquitination of Myc by FBW7 not only affects protein turnover but also alters the functional properties of Myc. Indeed, some recent evidence suggests that ubiquitination of Myc affects its transcriptional properties and that not all ubiquitination events target Myc to the proteasome (Kim et al., 2003; von der Lehr et al., 2003; Adhikary et al., 2005; Otto et al., 2009). Whatever the exact answer is: the analysis of Myc ubiquitination and turnover is a key to our understanding of the protein and is likely to offer many more surprises.

References

Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL (1985) The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318: 533–538
Adhikary S, Marinoni F, Hock A, Hulmele E, Popov N, Beier R, Bernard S, Quarto M, Capra M, Goettig S, Kogl U, Scheffner M, Helin K, Eilers M. (2005) The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation. Cell 123: 409–421
Bahram F, von der Lehr N, Cetinkaya C, Larsson LG (2000) c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 95: 2104–2110
Hemmam MT, Gri C, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C, Cleveland JL, Tansey WP, Lowe SW (2005) Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436: 807–811
Kim SY, Herbst A, Tworkowski KA, Salghetti SE, Tansey WP (2003) Skp2 regulates myc protein stability and activity. Mol Cell 11: 1177–1188
Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, Popov N, Kenney AM, Schulte JH, Beijersbergen R, Christiansen H, Berwanger B, Eilers M (2009) Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 15: 67–78
Popov N, Wenzel M, Madiredo M, Zhang D, Beijersbergen R, Bernards R, Moll R, Elledge SJ, Eilers M (2007) The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol 9: 765–774
Rajagopalan H, Jallepalli PV, Raju C, Velculescu VE, Kinzler KW, Vogelstein B, Lengauer C (2004) Inactivation of hCDC4 can cause chromosomal instability. Nature 428: 77–81
von der Lehr N, Johansson S, Wu S, Bahram F, Castell A, Cetinkaya C, Hydrbring P, Weidung I, Nakayama K, Nakayama KI, Söderberg O, Kerppola TK, Larsson LG (2003) The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell 11: 1189–1200
Welcker M, Orian A, Jin J, Grim JA, Harper JW, Eisenman RN, Clurman BE (2004) The FBw7 tumor suppressor regulates glyco- gen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci USA 101: 9085–9090
Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K, Nakayama KI (2004) Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein FBW7. EMBO J 23: 2116–2125

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits distribution, and reproduction in any medium, provided the original author and source are credited. This license does not permit commercial exploitation without specific permission.

The EMBO Journal is published by Nature Publishing Group on behalf of European Molecular Biology Organization. This article is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 Licence. [http://creativecommons.org/licenses/by-nc-nd/3.0]